Skip navigation


Current DateTime: 07:36:51 09 Nov 2009
LinksList Documentid: 24355697

FEATURED QUIZZES


Current DateTime: 07:36:51 09 Nov 2009
LinksList Documentid: 33793611

Current DateTime: 07:36:51 09 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
Roche May Have to Boost Genentech Bid
By: CNBC.com | 21 Jul 2008 | 08:51 AM ET
Text Size

Roche's $43.7 billion offer to buy Genentech may not be the last one, Birgit Kulhoff, pharmaceuticals analyst at Rahn & Bodmer told CNBC Monday.

Swiss-based pharmaceutical company Roche, which already owns 55.9 percent of Genentech [DNA  Loading...      ()   ], is offering $89 per share to buy up the remaining stake, a 9 percent premium to the biotech company's closing share price on Friday.

"I think for Roche this proposed deal at least at the current terms is positive, for Genentech I think they probably will not be too happy because it really gives rather low valuation to Genentech," Kulhoff told "Worldwide Exchange." "I think we might see higher bids in the end."

A combined entity would have a bigger marketing clout, would cooperate better in research and development and would lower costs, she said.

"In the end it could make sense, but of course that all depends on the price," Kulhoff said.

It will be very important for Roche to maintain the culture of research and development at Genentech and to keep the innovation there going, she added.

Consolidation might continue with pharmaceutical companies buying biotech firms, as the valuations of biotech companies are still reasonable, Kulhoff said.

"That could be the start of a bigger M&A wave," she added.

© 2009 CNBC.com
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • Do free market libertarians really believe what they say about ethics and shareholder value? The Big Money takes a look.
  • Jim Cramer
  • Cramer did the research and found eight stocks that lead the pack. Read on to get his top picks.
  • On the anniversary of the fall of the Berlin Wall, many in the former Eastern Bloc recall communism fondly.
  • Gavel
  • Software, biotech firms, even banks are watching a particular Supreme Court argument today.
  • From politicians to CEOs to companies, here's your chance to vote for the winners and losers of 2009.
  • A new sinister Internet viruses can turn you into an unsuspecting collector of child pornography.
ADD COMMENTS
Remaining characters


Current DateTime: 03:21:08 09 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 08:52:06 09 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 06:53:35 09 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 08:52:07 09 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters